RT Journal Article
SR Electronic
T1 Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.30.21257971
DO 10.1101/2021.05.30.21257971
A1 Rüdiger Groß
A1 Michelle Zanoni
A1 Alina Seidel
A1 Carina Conzelmann
A1 Andrea Gilg
A1 Daniela Krnavek
A1 Sümeyye Erdemci-Evin
A1 Benjamin Mayer
A1 Markus Hoffmann
A1 Stefan Pöhlmann
A1 Alexandra Beil
A1 Joris Kroschel
A1 Bernd Jahrsdörfer
A1 Hubert Schrezenmeier
A1 Frank Kirchhoff
A1 Jan Münch
A1 Janis A. Müller
YR 2021
UL http://medrxiv.org/content/early/2021/07/15/2021.05.30.21257971.abstract
AB Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited. We aimed to evaluate the reactogenicity, humoral and cellular immune responses towards different SARS-CoV-2 variants after a heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination and analyzed a cohort of 26 individuals aged 25-46 (median 30.5) years that received a ChAdOx1 nCoV-19 prime followed by a BNT162b2 boost after an 8- week interval. Self-reported solicited symptoms after ChAdOx1 nCoV-19 prime were in line with previous reports and less severe after the BNT162b2 boost. Antibody titers increased significantly over time resulting in strong neutralization titers two weeks after the BNT162b2 boost. Neutralizing activity against the prevalent strain B.1.1.7 (Alpha) and immune-evading VOC B.1.351 (Beta) was ∼4-fold higher than in individuals receiving homologous BNT162b2 vaccination. No difference was seen in neutralization of VOI B.1.617 (Kappa). In addition, the heterologous vaccination induced CD4+ and CD8+ T cells reactive to SARS-CoV-2 spike peptides of all analyzed variants; Wuhan-Hu-1, B.1.1.7, B.1.351, and P.1 (Gamma). In conclusion, heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination regimen is not associated with serious adverse events and results in a potent humoral immune response and elicits T cell reactivity. Variants B.1.1.7, B.1.351 and B.1.617.1 are potently neutralized by sera of all participants and reactive T cells recognize spike peptides of all tested variants. These results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Union Horizon 2020 research and innovation programme, the German Research Foundation, the BMBF, the Robert Koch Institute, the Baden-Wuerttemberg Stiftung, the Ministry for Science, Research and the Arts of Baden-Wuerttemberg and the county of Lower Saxony.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of Ulm university (99/21; 31/21).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request after positive peer-review evaluation.